Source: Eur Respir J 2009; 33: 521
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
van der Eerden M. M., Boersma W. G.. Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia. Eur Respir J 2009; 33: 521

Member's Comments

No comment yet.

Related content which might interest you: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Immunomodulating therapy and the risk of severe pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 353s Year: 2002 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Prediction of complications development and lethal outcome in patients with community-acquired pneumonia Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2 Source: Eur Respir J, 56 (3) 2002439; 10.1183/13993003.02439-2020 Year: 2020 Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2 Source: Eur Respir J, 56 (3) 2002961; 10.1183/13993003.02961-2020 Year: 2020 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Intrahospital cardiovascular complications in severe community-acquired pneumonia Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Compliance with severe sepsis bundles and its effect on outcomes of severe pneumonia and septic shock in a Chinese hospital Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Analysis of the mortality caused by community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 544s Year: 2005 Treatment failure of severe and ventilator-associated pneumonia Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012